Cargando…

Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3

Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established...

Descripción completa

Detalles Bibliográficos
Autores principales: Tasso, Bruno, Mattioli, Laura Beatrice, Tonelli, Michele, Boido, Vito, Chiarini, Alberto, Sparatore, Fabio, Budriesi, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574513/
https://www.ncbi.nlm.nih.gov/pubmed/37836759
http://dx.doi.org/10.3390/molecules28196916
_version_ 1785120711902232576
author Tasso, Bruno
Mattioli, Laura Beatrice
Tonelli, Michele
Boido, Vito
Chiarini, Alberto
Sparatore, Fabio
Budriesi, Roberta
author_facet Tasso, Bruno
Mattioli, Laura Beatrice
Tonelli, Michele
Boido, Vito
Chiarini, Alberto
Sparatore, Fabio
Budriesi, Roberta
author_sort Tasso, Bruno
collection PubMed
description Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established reference drugs. According to their structures, the tested compounds are assembled into three subsets: (a) N-(quinolizidinyl-alkyl)-benzamides; (b) 2-(benzotriazol-2-yl)methyl-1-(quinolizidinyl)alkyl-benzimidazoles; (c) N-substituted cytisines. All compounds but two displayed antiarrhythmic activity that was potent for compounds 4, 1, 6, and 5 (in ascending order). The last compound (N-(3,4,5-trimethoxybenzoyl)aminohomolupinane) was outstanding, exhibiting a nanomolar potency (EC(50) = 0.017 µM) for the increase in the threshold of ac-arrhythmia. The tested compounds shared strong negative inotropic activity; however, this does not compromise the value of their antiarrhythmic action. On the other hand, only moderate or modest negative chronotropic and vasorelaxant activities were commonly observed. Compound 5, which has high antiarrhythmic potency, a favorable cardiovascular profile, and is devoid of antihypertensive activity in spontaneously hypertensive rats, represents a lead worthy of further investigation.
format Online
Article
Text
id pubmed-10574513
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105745132023-10-14 Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3 Tasso, Bruno Mattioli, Laura Beatrice Tonelli, Michele Boido, Vito Chiarini, Alberto Sparatore, Fabio Budriesi, Roberta Molecules Article Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established reference drugs. According to their structures, the tested compounds are assembled into three subsets: (a) N-(quinolizidinyl-alkyl)-benzamides; (b) 2-(benzotriazol-2-yl)methyl-1-(quinolizidinyl)alkyl-benzimidazoles; (c) N-substituted cytisines. All compounds but two displayed antiarrhythmic activity that was potent for compounds 4, 1, 6, and 5 (in ascending order). The last compound (N-(3,4,5-trimethoxybenzoyl)aminohomolupinane) was outstanding, exhibiting a nanomolar potency (EC(50) = 0.017 µM) for the increase in the threshold of ac-arrhythmia. The tested compounds shared strong negative inotropic activity; however, this does not compromise the value of their antiarrhythmic action. On the other hand, only moderate or modest negative chronotropic and vasorelaxant activities were commonly observed. Compound 5, which has high antiarrhythmic potency, a favorable cardiovascular profile, and is devoid of antihypertensive activity in spontaneously hypertensive rats, represents a lead worthy of further investigation. MDPI 2023-10-03 /pmc/articles/PMC10574513/ /pubmed/37836759 http://dx.doi.org/10.3390/molecules28196916 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tasso, Bruno
Mattioli, Laura Beatrice
Tonelli, Michele
Boido, Vito
Chiarini, Alberto
Sparatore, Fabio
Budriesi, Roberta
Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3
title Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3
title_full Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3
title_fullStr Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3
title_full_unstemmed Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3
title_short Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3
title_sort further quinolizidine derivatives as antiarrhythmic agents- 3
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574513/
https://www.ncbi.nlm.nih.gov/pubmed/37836759
http://dx.doi.org/10.3390/molecules28196916
work_keys_str_mv AT tassobruno furtherquinolizidinederivativesasantiarrhythmicagents3
AT mattiolilaurabeatrice furtherquinolizidinederivativesasantiarrhythmicagents3
AT tonellimichele furtherquinolizidinederivativesasantiarrhythmicagents3
AT boidovito furtherquinolizidinederivativesasantiarrhythmicagents3
AT chiarinialberto furtherquinolizidinederivativesasantiarrhythmicagents3
AT sparatorefabio furtherquinolizidinederivativesasantiarrhythmicagents3
AT budriesiroberta furtherquinolizidinederivativesasantiarrhythmicagents3